The Progression Patterns and Subsequent Treatments of First‐Line Immunotherapy in Advanced Non‐Small Cell Lung Cancer: A Retrospective Cohort Study
Thoracic Cancer · 2025-10 · 16 (20)
DOI: 10.1111/1759-7714.70173 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Thoracic Cancer, online erschienen am 15.10.2025. Verfasst von Qi He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Med…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Major Project.
Abstract (Originalsprache)
Background
In metastatic non‐small cell lung cancer (NSCLC) patients receiving first‐line immune checkpoint inhibitors (ICIs), the real‐world progression patterns and subsequent treatment outcomes remain controversial.
Methods
We retrospectively analyzed patients with stage IV NSCLCs treated with first‐line immunotherapy between January 2017 and June 2023. Clinico‐demographic and treatment data were obtained from an electronic medical record system. Progression patterns were categorized by: (1) Progression in different organs; (2) Progression in existing or new lesions; and (3) Oligoprogression versus systemic progression. Survival was assessed using the Kaplan–Meier method and Cox proportional hazards models.
Results
Among 157 patients, 67.5% experienced systemic progression, and 49.0% had progression in existing lesions. The most common organs with progression were the lung (81.5%), lymph nodes (35.0%), and pleural effusion (24.2%). Median post‐progression survival (PPS) was superior in oligoprogression versus systemic progression (22.4 vs. 10.9 months, p = 0.012). Patients with extrapulmonary progression (8.2 vs. 22.9 months, p < 0.001) or progression in new lesions (9.6 vs. 25.3 months, p = 0.029) showed decreased PPS. In multivariate Cox regression, ECOG PS of 2–4 (HR: 2.26, p = 0.003), tumor stage of IVB (HR: 1.74, p = 0.013), and extrapulmonary progression (HR: 2.05, p = 0.002) were associated with decreased PPS. Subsequent treatments containing ICIs improved survival compared to regimens without ICIs (29.0 vs. 11.3 months, p = 0.004), particularly in patients with systemic progression (19.3 vs. 9.2 months, p = 0.013).
Conclusion
Most metastatic NSCLCs on first‐line immunotherapy experienced systemic progression. Oligoprogression and progression only in existing lesions showed better prognoses, whereas extrapulmonary progression indicated worse survival. Subsequent ICI‐containing treatments had improved survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Yan Xu, Meng-Zhao Wang
Förderung
- National Science and Technology Major Project
Zitieren
APA
He, Q., Guo, X. B., Chen, Y. R., Gao, X. X., Chen, M. J., Zhao, J., Zhong, W., Xu, Y., & Wang, M. Z. (2025). The Progression Patterns and Subsequent Treatments of First‐Line Immunotherapy in Advanced Non‐Small Cell Lung Cancer: A Retrospective Cohort Study. Thoracic Cancer, 16(20). https://doi.org/10.1111/1759-7714.70173
Vancouver
He Q, Guo XB, Chen YR, Gao XX, Chen MJ, Zhao J, et al. The Progression Patterns and Subsequent Treatments of First‐Line Immunotherapy in Advanced Non‐Small Cell Lung Cancer: A Retrospective Cohort Study. Thoracic Cancer. 2025;16(20). doi:10.1111/1759-7714.70173
BibTeX
@article{He2025,
author = {He, Qi and Guo, Xiao-Bei and Chen, Yu-Rou and Gao, Xiao-Xing and Chen, Min-Jiang and Zhao, Jing and Zhong, Wei and Xu, Yan and Wang, Meng-Zhao},
title = {The Progression Patterns and Subsequent Treatments of First‐Line Immunotherapy in Advanced Non‐Small Cell Lung Cancer: A Retrospective Cohort Study},
journal = {Thoracic Cancer},
year = {2025},
volume = {16},
number = {20},
doi = {10.1111/1759-7714.70173}
}
EUVIMED